James R.  Empfield net worth and biography

James Empfield Biography and Net Worth

Dr. Empfield joined Xenon in 2016 and is employed by our wholly owned subsidiary, Xenon Pharmaceuticals USA Inc., as our Executive Vice President, Drug Discovery. Prior to joining us, Dr. Empfield served as Vice President, Drug Discovery and Chemistry; Co-Site Head of Research, Boston at Vertex Pharmaceuticals Inc. from 2011 until August 2015, where he was jointly responsible for the entire Boston research organization and for delivery of lead optimization projects into preclinical development. From 2006 to 2011, Dr. Empfield was Director, CNS Chemistry Department at Astrazeneca Pharmaceuticals LP and held various other positions at Astrazeneca Pharmaceuticals from 1990 to 2006. Dr. Empfield has a Ph.D. in Chemistry from the University of Pennsylvania, a M.S. in Chemistry from Bucknell University and a B.Sc. in Chemistry from Lebanon Valley College.

What is James R. Empfield's net worth?

The estimated net worth of James R. Empfield is at least $405,000.00 as of August 12th, 2022. Dr. Empfield owns 10,000 shares of Xenon Pharmaceuticals stock worth more than $405,000 as of April 27th. This net worth evaluation does not reflect any other assets that Dr. Empfield may own. Additionally, Dr. Empfield receives a salary of $323,430.00 as EVP at Xenon Pharmaceuticals. Learn More about James R. Empfield's net worth.

How old is James R. Empfield?

Dr. Empfield is currently 63 years old. There are 6 older executives and no younger executives at Xenon Pharmaceuticals. The oldest executive at Xenon Pharmaceuticals is Ms. Shelley McCloskey B.A., Executive Vice President of Human Resources, who is 64 years old. Learn More on James R. Empfield's age.

What is James R. Empfield's salary?

As the EVP of Xenon Pharmaceuticals Inc., Dr. Empfield earns $323,430.00 per year. There are 5 executives that earn more than Dr. Empfield. The highest earning executive at Xenon Pharmaceuticals is Ms. Sherry Aulin, Chief Financial Officer, who commands a salary of $3,030,000.00 per year. Learn More on James R. Empfield's salary.

How do I contact James R. Empfield?

The corporate mailing address for Dr. Empfield and other Xenon Pharmaceuticals executives is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. Xenon Pharmaceuticals can also be reached via phone at (604) 484-3300 and via email at [email protected]. Learn More on James R. Empfield's contact information.

Has James R. Empfield been buying or selling shares of Xenon Pharmaceuticals?

James R. Empfield has not been actively trading shares of Xenon Pharmaceuticals in the last ninety days. Most recently, James R. Empfield sold 57,743 shares of the business's stock in a transaction on Friday, August 12th. The shares were sold at an average price of $38.31, for a transaction totalling $2,212,134.33. Following the completion of the sale, the executive vice president now directly owns 10,000 shares of the company's stock, valued at $383,100. Learn More on James R. Empfield's trading history.

Who are Xenon Pharmaceuticals' active insiders?

Xenon Pharmaceuticals' insider roster includes James Empfield (EVP), Frank Holler (Director), Christopher Kenney (Insider), Ian Mortimer (President and Chief Executive Officer), Gary Patou (Director), Simon Pimstone (Director), Robin Sherrington (EVP), Dawn Svoronos (Director), and Christopher Von Seggern (Insider). Learn More on Xenon Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Xenon Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 150,698 shares worth more than $6,077,150.31. The most recent insider tranaction occured on March, 7th when EVP Sherrington Robin sold 7,137 shares worth more than $330,300.36. Insiders at Xenon Pharmaceuticals own 5.4% of the company. Learn More about insider trades at Xenon Pharmaceuticals.

Information on this page was last updated on 3/7/2024.

James R. Empfield Insider Trading History at Xenon Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/12/2022Sell57,743$38.31$2,212,134.3310,000View SEC Filing Icon  
3/7/2022Sell32,853$30.54$1,003,330.62View SEC Filing Icon  
8/15/2017Buy10,000$2.48$24,800.0010,000View SEC Filing Icon  
See Full Table

James R. Empfield Buying and Selling Activity at Xenon Pharmaceuticals

This chart shows James R Empfield's buying and selling at Xenon Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Xenon Pharmaceuticals Company Overview

Xenon Pharmaceuticals logo
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
Read More

Today's Range

Now: $40.50
Low: $39.80
High: $40.87

50 Day Range

MA: $43.95
Low: $39.50
High: $49.63

2 Week Range

Now: $40.50
Low: $27.99
High: $50.99

Volume

320,772 shs

Average Volume

398,124 shs

Market Capitalization

$3.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15